Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer

(1) We hypothesized that adding concurrent stereotactic ablative radiotherapy (SAbR) would increase the time to progression in patients with metastatic castrate-resistant prostate cancer (mCRPCA) treated with sipuleucel-T. (2) Patients with a history of prostate cancer (PC), radiographic evidence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannan, Raquibul, Dohopolski, Michael J., Pop, Laurentiu M., Mannala, Samantha, Watumull, Lori, Mathews, Dana, Gao, Ang, Garant, Aurelie, Arriaga, Yull E., Bowman, Isaac, Chung, Jin-Sung, Wang, Jing, Ariizumi, Kiyoshi, Ahn, Chul, Timmerman, Robert, Courtney, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220346/
https://www.ncbi.nlm.nih.gov/pubmed/35740441
http://dx.doi.org/10.3390/biomedicines10061419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220346/
https://www.ncbi.nlm.nih.gov/pubmed/35740441
http://dx.doi.org/10.3390/biomedicines10061419

Ejemplares similares